PBAXU
Income statement / Annual
Last year (2024), Phoenix Biotech Acquisition Corp.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Phoenix Biotech Acquisition Corp.'s net income was -$11.09 M.
See Phoenix Biotech Acquisition Corp.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2024 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$254.83 K
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$7.08 M
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$9.12 M
|
$2.84 M
|
$431.50
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$251.27 K
|
| Selling, General & Administrative Expenses |
$9.12 M
|
$2.84 M
|
$251.71 K
|
| Other Expenses |
$0.00
|
$64.05 K
|
-$80.32 K
|
| Operating Expenses |
$16.20 M
|
$2.91 M
|
$332.03 K
|
| Cost And Expenses |
$0.00
|
$2.91 M
|
$332.03 K
|
| Interest Income |
$0.00
|
$2.84 M
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
-$5.67 M
|
$236.56 K
|
| EBITDA |
-$16.20 M |
-$5.74 M |
-$332.03 K |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$5.11 M
|
$2.84 K
|
-$385.00
|
| Income Before Tax |
-$11.09 M
|
-$68.58 K
|
-$332.42 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$599.16 K
|
-$16.87 K
|
| Net Income |
-$11.09 M
|
-$667.74 K
|
-$315.55 K
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-0.22 |
-0.0099 |
-0.0046 |
| EPS Diluted |
-0.22 |
-0.0099 |
-0.0046 |
| Weighted Average Shares Out |
$49.68 M
|
$67.48 M
|
$68.94 M
|
| Weighted Average Shares Out Diluted |
$49.68 M
|
$67.48 M
|
$68.94 M
|
| Link |
|
|
|
